Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 22, 2020
Daily News
October 22, 2020
- MHLW Wants Distribution Improvement Confab by Year-End, Reckless Discounts Seen with Pricey Meds
October 22, 2020
- Kyowa Kirin Delivers Positive PIIb Data for Parkinson’s Med KW-6356
October 22, 2020
- Xenograft Library Derived from Japanese Cancer Patients Now Up and Running
October 22, 2020
- Aducanumab Filed in Europe: Biogen/Eisai
October 22, 2020
- Chugai Licenses Antibody Engineering Tech to Novo
October 22, 2020
- GSK Sets Up Oncology Biz Unit in Japan; Multiple Late-Stage Assets in Pipeline
October 22, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…